SCHEMBL15078418

SCHEMBL15078418

COCOC(c1ccccc1Cl)C(OC(N)=O)C(C)C

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.36
CXCL8 P10145 1/20 0.34
CASP1 P29466 1/20 0.34
ATM Q13315 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
P2RX7 Q99572 1/20 0.32
CTSA P10619 3/20 0.32
ALDH1A1 P00352 2/20 0.32
NISCH Q9Y2I1 1/20 0.32
LMNA P02545 2/20 0.32
AVPR2 P30518 1/20 0.32
AVPR1A P37288 1/20 0.32
MAPT P10636 1/20 0.31
OPRM1 P35372 1/20 0.31
OPRL1 P41146 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15078416 1.00 AOC3 (0.36) AOC3CXCL8CASP1ATMADRB2
SCHEMBL15078373 1.00 AOC3 (0.36) AOC3CXCL8CASP1ATMADRB2
SCHEMBL10329426 0.87 CXCL8 (0.36) AOC3CXCL8CASP1ATMADRB2
SCHEMBL15078370 0.87 CXCL8 (0.36) AOC3CXCL8CASP1ATMADRB2
SCHEMBL15078412 0.87 CXCL8 (0.36) AOC3CXCL8CASP1ATMADRB2
SCHEMBL15078410 0.87 CXCL8 (0.36) AOC3CXCL8CASP1ATMADRB2
SCHEMBL15078413 0.87 CXCL8 (0.36) AOC3CXCL8CASP1ATMADRB2
SCHEMBL15078457 0.86 HPGD (0.32) CXCL8ALDH1A1
SCHEMBL15078406 0.86 HPGD (0.32) CXCL8ALDH1A1
SCHEMBL15078468 0.86 HPGD (0.32) CXCL8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
US-9504668-B2 Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-29 US disclosed
US-9504668-B2 Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-29 US disclosed
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed
US-9029589-B2 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-05-12 US disclosed
US-9029589-B2 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-05-12 US disclosed
WO-2014142519-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2014-09-18 WO disclosed
WO-2013100566-A1 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-07-04 WO disclosed
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME MYLK, PDE3A, TNNC1 AOC3 3584/4885CXCL8 3386/4885CASP1 2375/4885
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME SCN1A, GABARAPL1, NAA10 AOC3 2921/4885CXCL8 3744/4885CASP1 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.